The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium. Arbli, an angiotensin II receptor blocker, is indicated for the treatment of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback